You are here
A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.
The meta-analysis included 60 clinical trials for short-term (up to 16 weeks) and long-term (44-60 weeks) efficacy with brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa. Moderate to severe psoriasis was assessed by the Psoriasis Area and Severity Index assessment of 75%, 90%, and 100% responses.
From weeks 10 to 16, the highest PASI 90 rates were seen with
- risankizumab-rzaa (71.6%)
- brodalumab (70.8%)
- ixekizumab (70.6%)
- guselkumab (67.3%)
From weeks 44 to 60, the PASI 90 rates were:
- risankizumab-rzaa (79.4%)
- guselkumab (76.5%)
- brodalumab (74.0%)
- ixekizumab (73.9%)
These data show high level, comparative efficacy with IL-17 and IL-23 targeted biologics in moderate to severe plaque psoriasis.